Abstract

The artificial pancreas (AP) represents a transformative approach in the management of type 1 diabetes mellitus, 
aiming to automate insulin delivery and maintain glucose homeostasis. This narrative review synthesizes current 
knowledge on AP technologies, including hybrid and fully closed-loop systems, sensor modalities, actuation 
mechanisms, control algorithms, and clinical outcomes. Historical development from early intravenous systems to 
modern wearable devices highlights the evolution of closed-loop insulin delivery and bihormonal approaches. 
Advances in continuous glucose monitoring, predictive algorithms, and personalized control strategies have 
demonstrated significant improvements in glycemic control, reduction of hypoglycemic events, and enhanced 
patient quality of life across pediatric, adolescent, and adult populations. Despite clinical successes, challenges 
persist in sensor accuracy, real-world usability, regulatory approval, and integration of multi-hormonal or multi
drug approaches. Ethical considerations, patient adherence, and methodological limitations in clinical evaluations 
further underscore the need for ongoing research. Future directions emphasize standardization of key performance 
metrics, enhanced interoperability, and expansion of artificial pancreas accessibility to diverse populations. Overall, 
AP technologies offer a promising pathway toward replicating physiological insulin regulation and improving 
outcomes for individuals with type 1 diabetes.